Financial Personal
Pfizer cuts full-year outlook due to declining sales of Covid-19-related products
Shares of Pfizer are in retreat on the first day of trading after the drug company said sales of its COVID-19 vaccine and its coronavirus treatment are in less than expected and cut revenue expectations for the year by $9 billion. Falling sales of bo
Shares of Pfizer are in retreat on the first day of trading after the drug company said sales of its COVID-19 vaccine and its coronavirus treatment are in less than expected and cut revenue expectations for the year by $9 billion. Read More
Related
Share this page
Guest Posts by Easy Branches